MA39711A - Conjugués d'une fraction d'il-15 et d'un polymère - Google Patents

Conjugués d'une fraction d'il-15 et d'un polymère

Info

Publication number
MA39711A
MA39711A MA039711A MA39711A MA39711A MA 39711 A MA39711 A MA 39711A MA 039711 A MA039711 A MA 039711A MA 39711 A MA39711 A MA 39711A MA 39711 A MA39711 A MA 39711A
Authority
MA
Morocco
Prior art keywords
conjugates
moiety
polymer
nonpeptidic
methods
Prior art date
Application number
MA039711A
Other languages
English (en)
Inventor
Thomas Chang
Deborah H Charych
Peter Benedict Kirk
Xiaofeng Liu
Original Assignee
Nektar Therapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nektar Therapeutics filed Critical Nektar Therapeutics
Publication of MA39711A publication Critical patent/MA39711A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2086—IL-13 to IL-16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/34—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from hydroxy compounds or their metallic derivatives
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/34—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from hydroxy compounds or their metallic derivatives
    • C08G65/48—Polymers modified by chemical after-treatment

Abstract

L'invention concerne des conjugués d'une fraction d'il-11 et d'un ou de plusieurs polymères non peptidiques, solubles dans l'eau. Typiquement, le polymère non peptidique, soluble dans l'eau est un poly(éthylène glycol) ou un dérivé de celui-ci. L'invention porte également, entre autres, sur des compositions comprenant des conjugués, des procédés de fabrication de conjugués et des procédés d'administration de compositions à un individu.
MA039711A 2014-04-03 2015-03-31 Conjugués d'une fraction d'il-15 et d'un polymère MA39711A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201461974914P 2014-04-03 2014-04-03

Publications (1)

Publication Number Publication Date
MA39711A true MA39711A (fr) 2015-10-08

Family

ID=54241432

Family Applications (1)

Application Number Title Priority Date Filing Date
MA039711A MA39711A (fr) 2014-04-03 2015-03-31 Conjugués d'une fraction d'il-15 et d'un polymère

Country Status (12)

Country Link
US (1) US20170035898A1 (fr)
EP (2) EP3139947B8 (fr)
JP (2) JP6728055B2 (fr)
KR (1) KR102432169B1 (fr)
CN (1) CN106456716A (fr)
AU (3) AU2015240806B2 (fr)
CA (1) CA2942571C (fr)
ES (1) ES2876433T3 (fr)
IL (1) IL248169A0 (fr)
MA (1) MA39711A (fr)
MX (2) MX2016012908A (fr)
WO (1) WO2015153753A2 (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105209054A (zh) 2013-04-18 2015-12-30 阿尔莫生物科技股份有限公司 使用白细胞介素-10治疗疾病和病症的方法
US9823255B2 (en) 2013-06-17 2017-11-21 Armo Biosciences, Inc. Method for assessing protein identity and stability
WO2015031316A1 (fr) 2013-08-30 2015-03-05 Armo Biosciences, Inc. Méthodes d'utilisation d'interleukine 10 dans le traitement de maladies et de troubles
KR20160079114A (ko) 2013-11-11 2016-07-05 아르모 바이오사이언시스 인코포레이티드 질환 및 장애를 치료하기 위한 인터류킨-10을 사용하는 방법
US10293043B2 (en) 2014-06-02 2019-05-21 Armo Biosciences, Inc. Methods of lowering serum cholesterol
MX2017004838A (es) 2014-10-14 2017-10-16 Armo Biosciences Inc Composiciones de interleucina-15 y usos de estas.
EP3209320B1 (fr) 2014-10-22 2023-03-08 Armo Biosciences, Inc. Procédés d'utilisation de l'interleukine-10 pour le traitement de maladies et de troubles
WO2016126615A1 (fr) 2015-02-03 2016-08-11 Armo Biosciences, Inc. Procédés d'utilisation de l'interleukine-10 pour le traitement de maladies et de troubles
EP3302547A1 (fr) 2015-05-28 2018-04-11 Armo Biosciences, Inc. Interleukine 10 pégylée utilisée pour le traitement du cancer
JP7053453B2 (ja) 2015-08-25 2022-04-12 アルモ・バイオサイエンシーズ・インコーポレイテッド 疾患及び障害を治療するためのインターロイキン１０の使用方法
JP7407511B2 (ja) * 2015-10-08 2024-01-04 ネクター セラピューティクス ＩＬ－２Ｒβ選択的作動薬と長時間作用型ＩＬ－１５作動薬との併用
JP2019503348A (ja) * 2015-12-21 2019-02-07 アルモ・バイオサイエンシーズ・インコーポレイテッド インターロイキン−１５組成物及びその使用
US11472856B2 (en) 2016-06-13 2022-10-18 Torque Therapeutics, Inc. Methods and compositions for promoting immune cell function
JP7316222B2 (ja) * 2017-05-15 2023-07-27 ネクター セラピューティクス 長時間作用型インターロイキン－１５受容体作動薬並びに関連する免疫治療組成物及び方法
AU2018328209A1 (en) 2017-09-05 2020-04-23 Torque Therapeutics, Inc. Therapeutic protein compositions and methods of making and using the same
AR114445A1 (es) 2018-02-26 2020-09-09 Synthorx Inc Conjugados de il-15, y sus usos
MX2021005485A (es) * 2018-11-09 2021-06-18 Nektar Therapeutics Agonista del receptor de interleuquina-15 de accion prolongada con otro agente farmacologicamente activo.
US20220193253A1 (en) * 2019-04-26 2022-06-23 Prolynx Llc Slow-release cytokine conjugates
US11248025B2 (en) 2019-06-03 2022-02-15 Medikine, Inc. IL-2alpha receptor subunit binding compounds
AU2020337869A1 (en) * 2019-08-23 2022-03-03 Synthorx, Inc. IL-15 conjugates and uses thereof
TW202304517A (zh) * 2021-03-29 2023-02-01 大陸商北京軒義醫藥科技有限公司 蛋白—大分子綴合物及其使用方法
AU2022299404A1 (en) 2021-06-23 2023-12-07 Cytune Pharma Interleukin 15 variants
WO2023288226A2 (fr) * 2021-07-12 2023-01-19 Nektar Therapeutics Formes polymères modifiées de l'interféron-gamma et procédés d'utilisation
WO2023133595A2 (fr) 2022-01-10 2023-07-13 Sana Biotechnology, Inc. Méthodes de dosage et d'administration ex vivo de particules lipidiques ou de vecteurs viraux ainsi que systèmes et utilisations associés
WO2023193015A1 (fr) 2022-04-01 2023-10-05 Sana Biotechnology, Inc. Polythérapies d'agoniste de récepteur de cytokine et de vecteur viral

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5166322A (en) 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
US6110721A (en) * 1993-11-12 2000-08-29 Gilead Sciences, Inc. Polypeptides and coagulation therapy
US5446090A (en) 1993-11-12 1995-08-29 Shearwater Polymers, Inc. Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
ES2151927T3 (es) 1994-04-06 2001-01-16 Immunex Corp Interleuquina-15.
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US5795966A (en) 1995-02-22 1998-08-18 Immunex Corp Antagonists of interleukin-15
US7008624B1 (en) * 1995-02-22 2006-03-07 Immunex Corporation Antagonists of interleukin-15
EP1061954B1 (fr) 1998-03-12 2004-06-09 Nektar Therapeutics Al, Corporation Derives de poly(ethylene glycol) avec groupes reactifs proximaux
WO2001062827A2 (fr) 2000-02-22 2001-08-30 Shearwater Corporation Derives de polymere n-maleimidyle
CA2509153C (fr) * 2002-12-31 2013-04-16 Nektar Therapeutics Al, Corporation Polymeres a terminaison maleimide hydrolytiquement stables
JP4490413B2 (ja) 2003-01-06 2010-06-23 ネクター セラピューティクス アラバマ，コーポレイション チオール選択的水溶性ポリマー誘導体
JP2007506789A (ja) * 2003-09-25 2007-03-22 ザイモジェネティクス， インコーポレイテッド Ｉｌ−２１を用いた自己免疫疾患の治療方法
AR050693A1 (es) * 2004-08-11 2006-11-15 Zheng Xin Xiao Composiciones que contienen interleuquina-15 mutante y supresion de una respuesta inmune.
US20060104945A1 (en) 2004-10-05 2006-05-18 Choi Yong S Enhancement of B cell proliferation by IL-15
US20060257361A1 (en) * 2005-04-12 2006-11-16 Government Of The Us, As Represented By The Secretary, Department Of Health And Human Services Novel form of interleukin-15, Fc-IL-15, and methods of use
WO2006138572A2 (fr) 2005-06-16 2006-12-28 Nektar Therapeutics Al, Corporation Conjugues a liaison degradable et reactifs polymeres utilises dans la preparation de ces conjugues
KR101508621B1 (ko) 2007-02-28 2015-04-07 세리나 쎄라퓨틱스, 인코포레이티드 활성화된 폴리옥사졸린 및 이를 포함하는 조성물
JP5775820B2 (ja) * 2008-10-21 2015-09-09 バクスター・インターナショナル・インコーポレイテッドＢａｘｔｅｒ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｉｎｃｏｒｐ０Ｒａｔｅｄ 遊離可能ｐｅｇ試薬を有するプロドラッグｐｅｇタンパク質結合体において活性成分（インビトロ脱ペグ化）を決定する方法
KR101969601B1 (ko) * 2010-07-30 2019-04-17 박스알타 인코퍼레이티드 옥심 결합용 친핵성 촉매
EA037083B1 (ru) * 2010-11-12 2021-02-03 Нектар Терапьютикс Иммуномодулирующий конъюгат, включающий il-2 и водорастворимые полимеры
CN102145178B (zh) * 2011-04-15 2012-09-26 北京凯因科技股份有限公司 Peg化白介素15
WO2013020079A2 (fr) * 2011-08-04 2013-02-07 Nektar Therapeutics Conjugués d'une fraction il-11 et d'un polymère

Also Published As

Publication number Publication date
ES2876433T3 (es) 2021-11-12
AU2015240806A1 (en) 2016-10-13
CN106456716A (zh) 2017-02-22
AU2015240806B2 (en) 2019-09-19
MX2016012908A (es) 2017-01-11
JP2020114875A (ja) 2020-07-30
WO2015153753A3 (fr) 2015-11-26
AU2019283778A1 (en) 2020-01-16
EP3139947B8 (fr) 2021-06-30
EP3139947B1 (fr) 2021-05-26
IL248169A0 (en) 2016-11-30
CA2942571A1 (fr) 2015-10-08
WO2015153753A2 (fr) 2015-10-08
KR102432169B1 (ko) 2022-08-11
JP6728055B2 (ja) 2020-07-22
CA2942571C (fr) 2023-09-19
JP2017511322A (ja) 2017-04-20
US20170035898A1 (en) 2017-02-09
EP3139947A4 (fr) 2018-01-17
KR20170005793A (ko) 2017-01-16
MX2021015492A (es) 2022-02-22
EP3139947A2 (fr) 2017-03-15
AU2021258008A1 (en) 2021-11-25
EP3919071A1 (fr) 2021-12-08

Similar Documents

Publication Publication Date Title
MX2021015492A (es) Conjugados de un resto de interleucina-15 (il-15) y un polimero.
MX2017011562A (es) Conjugados de un resto de il-7 y un polimero.
MX2017002333A (es) Conjugados novedosos de glicano y uso de los mismos.
EP3393500A4 (fr) Conjugués polymères ayant une antigénicité réduite et leurs procédés d'utilisation
WO2016040369A3 (fr) Activation des cellules inkt humaines par des glycolipides
CY1124425T1 (el) Συνθεσεις οι οποιες περιλαμβανουν συζευγματα φαρμακου αντισωματος-δουοκαρμυκινης
MX2017004838A (es) Composiciones de interleucina-15 y usos de estas.
MX2016009943A (es) Composiciones de nanotribologia y metodos relacionados que incluyen nanolaminas moleculares.
PH12017500555A1 (en) Modified phosphpors and compositions thereof
SG10201909805XA (en) Surface modified polymer compositions
EP3037475A4 (fr) Ester actif de phénoxycyclotriphosphazène, composition de résine sans halogènes et son utilisation
WO2015168225A3 (fr) Polycarbonates alcoxy, monomères bisphénol et leurs procédés de préparation et d'utilisation
EP4252681A3 (fr) Objets implantables, dispositifs de guidage, et procédés d'utilisation
TR201910057T4 (tr) Kauçuk bi̇leşi̇mleri̇
MX2013007230A (es) Sistemas de polimero.
MX2016004885A (es) Composicion de polimero funcionalizado.
WO2015035342A3 (fr) Conjugués polymère zwittérionique-facteur viii
MY192958A (en) Mixed decyl mercaptans compositions and methods of making same
NZ742805A (en) Anti-cd22 antibody-maytansine conjugates and methods of use thereof
MX2019009604A (es) Composicion quimica.
MX2018005085A (es) Nanoparticulas terapeuticas que comprenden un agente terapeutico y metodos de fabricacion y uso de las mismas.
WO2013020079A3 (fr) Conjugués d'une fraction il-11 et d'un polymère
MX2017000497A (es) Detergente en tableta para lavavajillas y metodos de fabricacion y de utilizacion del mismo.
MX2016010229A (es) Conjugados del factor vii.
EP3445899A4 (fr) Fibres fines à faible poids moléculaire ou à poids moléculaire élevé et fibre fines tpu